Cytokine network pathway

Cytokines are usually small polypeptides or glycoproteins with molecular weights ranging from 6 to 70 kDa. These molecules facilitate chemical signaling to regulate processes such as development, hematopoiesis, tissue repair, inflammation, and immune responses. Potent cytokines have pleiotropic activities and functional redundancy. They operate within a complex network where one cytokine can influence the production and activity of others,  playing a pivotal role in regulating the functions of target cells, including their differentiation, proliferation, apoptosis, and survival. When cytokines bind to receptors on these target cells, they activate intracellular signaling pathways that influence gene transcription, altering various biological activities. Moreover, target cells can interpret signals from different cytokines based on the concentration of the cytokines and the timing of their exposure, depending on specific receptor expression¹. The variation in cytokine levels found in different biological fluids such as serum, blood, stool, saliva, and sweat can offer valuable insights for diagnosing and predicting the prognosis of several diseases².

Download our cytokines poster

There are numerous classes of cytokines, including interferons (IFNs), interleukins (ILs), the tumor necrosis factor (TNF) superfamily, growth factors, and chemokines. These classes are vital for maintaining homeostasis and are involved in multiple processes and diseases. Based on their cellular origin, cytokines are often classified into two main types: type 1 and type 2 cytokines. Generally, type 1 cytokines support the development of a strong cellular immune response, while type 2 cytokines promote a strong humoral immune response. Some of these type 1 and type 2 cytokines are cross-regulatory, decreasing the level of the other types of cytokines³. Type 1 cytokines are produced by CD4⁺ T-helper 1 (T_h1) cells and include IL-2, IL-12, IFN-γ, and TNF-β. Type 2 cytokines are synthetised by CD4⁺ T-helper 2 (T_h2) cells and include IL-4, IL-5, IL-6, IL-10, and IL-13. Cytokines can also be categorized based on their pro-inflammatory or anti-inflammatory functions. Pro-inflammatory cytokines (such as IL-1β, IL-6, IL-8, IL-12, TNF-α, and interferons) drive inflammatory processes and activate immune cells. In contrast, anti-inflammatory cytokines (including IL-4, IL-10, IL-11, IL-13, IL-1 receptor antagonist (IL-1RA), and TGF-β) work to inhibit inflammation and suppress immune responses. Some cytokines, like IL-6, exhibit both pro-inflammatory and anti-inflammatory effects.

Understanding the different classifications of cytokines, particularly the pro-inflammatory and anti-inflammatory families, offers significant insights into the pathways involved in the host immune response. Depending on the circumstances, a single cytokine may be produced by different cells and display variable effects, leading to a range of immune responses. A dynamic balance between pro-inflammatory and anti-inflammatory cytokines is essential for regulating the immune system, as they play a crucial role in regulating and controlling inflammation. Pro-inflammatory cytokines are key in initiating and sustaining immune response to protect the host against irritation, injury, and infection, while anti-inflammatory cytokines aid in resolving inflammation and support recovery.

Studies have shown that an imbalanced cytokine profile can lead to different diseases initiationand progression like cancer, inflammatory bowel diseases, allergies, or aging by promoting chronic inflammation and enabling immune evasion. For instance, temporal dynamics show how cytokines, such as TNF-α and IL-17, may initially play a beneficial anti-tumor role in the early stages of the disease but can become pro-tumorigenic as the tumor advances⁴. In a similar way, complex networks are crucial in regulating autoimmune diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Therapies for inflammatory diseases, including RA and IBD, have specifically targeted cytokines believed to be vital in disease development, especially TNF-α and IL-17. While these therapies have been successful for many patients, not all individuals with IBD respond to anti-TNF-α treatment. Some patients have found relief through therapies targeting other cytokines, including IL-12, IL-13, and IL-6, in combination with other immunomodulators.

It is challenging to systematically understand the intricate interactions between cytokines and their target cells. Our Cytokine network poster provides a comprehensive and interactive pathway for this diverse and complex system, which involves numerous functions and connections.

References

1. Yi, M., Li, T., Niu, M. et al. Targeting cytokine and chemokine signaling pathways for cancer therapy.  Sig. Transduct. Target Ther.  9, 176 (2024).
2. Liu, C., Chu, D., Kalantar-Zadeh, K., George, J., Young, H. A. & Liu, G. Cytokines: From Clinical Significance to Quantification.  Adv. Sci. (Weinh)  8, e2004433 (2021).
3. Lucey, D. R., Clerici, M. & Shearer, G. M. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.  Clin. Microbiol. Rev.  9, 532–562 (1996).
4. Morel, P. A., Lee, R. E. C. & Faeder, J. R. Demystifying the cytokine network: Mathematical models point the way.  Cytokine  98, 115–123 (2017).